Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories
March 07, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has...
Delcath Announces 500th Commercial CHEMOSAT Treatment in Europe
February 02, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Announces Satisfaction of 2016 Convertible Note
February 01, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it...
Delcath Announces Special Protocol Agreement Modification With FDA
January 10, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that it...
Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology
January 09, 2018 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Announces Exit from Convertible Note
December 29, 2017 08:35 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces on...
Delcath Announces Preliminary Safety Analysis for Phase 3 Focus Trial
December 19, 2017 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology
December 05, 2017 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Enhances Board of Directors With Appointment of Industry Veteran, Dr. Simon Pedder
November 20, 2017 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that...
Delcath Announces Third Quarter 2017 Financial Results
November 14, 2017 18:41 ET
|
Delcath Systems, Inc.
NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces...